Clinical trial NCT03440450: A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
Official title: A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumors
Biliary Tract Cancer
Keywords: Liposomal gemcitabine
Lead sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.
Sponsor class: INDUSTRY
First posted: 2018-02-22
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Open label, dose escalation
Primary purpose: TREATMENT

Brief summary: To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors including biliary tract cancer

Detailed description: Dose-escalation Phase:

Eligible patients will receive FF-10832 in 28 day or 21 day cycles. Dosing will continue until progression of disease, observation of unacceptable adverse events, intercurrent illness, or changes in the patient's condition that prevents further study participation after discussion between the Investigator and the Medical Monitor. A number of cohorts will be enrolled sufficient to determine the MTD and to identify the RP2D.

Expansion Phase:

One cohort of biliary tract cancer will enroll up to 18 patients in a 21 day cycle.

Eligibility criteria: Inclusion Criteria:

1. Males and females ≥ 18 years of age
2. Histologically or cytologically confirmed metastatic solid tumor, relapsed or refractory to standard therapy, or for which no standard therapy is available that is expected to improve survival by at least three months
3. At least 3 weeks beyond the last chemotherapy (or 3 half-lives, whichever is shorter), radiotherapy, major surgery, or experimental treatment, and recovered from all acute toxicities (≤ Grade 1), prior to the first dose of FF-10832
4. Cohort expansion phase: (biliary tract cancer):

   * Histologically or cytologically confirmed cholangiocarcinoma or gall bladder carcinoma that is metastatic pancreatic adenocarcinoma following progression or relapseor unresectable
   * Measurable disease by RECIST 1.1
   * Progressed on at least one prior regimengemcitabine-cisplatin therapy or gemcitabine-based therapy if unable to tolerate cisplatin. Adjuvant therapy counts as such therapy.
   * Progressed on, declined on, or was ineligible for therapies directed against fibroblast growth factor (FGFR) and/or isocitrate dehydrogenase (IDH) mutations for tumors appropriately treated with such therapies
   * No more than 3 prior systemic therapies for their tumor. Please contact the medical monitor if there are any questions about eligibility.
   * A serum albumin level ≥ 3 g/dL on entry to the study
5. Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 1
6. Life expectancy of ≥ 3 months
7. Ability to provide written informed consent

Exclusion Criteria:

1. Patients who have not received standard/approved therapies expected to improve survival by at least 3 months
2. Prior hypersensitivity to gemcitabine
3. Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)

7. Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment

8. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results

9. Pregnant or breast-feeding

Primary outcomes:
measure: Determine incidence of Treatment Emergent Adverse Events (TEAE)
timeFrame: 2.5 years
measure: Identify dose-limiting toxicities (DLT) of FF-10832
timeFrame: 2.5 years
measure: Determine maximun tolerated dose (MTD) of FF-10832
timeFrame: 2.5 years
Secondary outcomes:
measure: Disease Assessment by CT or MRI scan for solid tumors
timeFrame: 2.5 years
measure: Disease Assessment by CT or MRI + PET scan for pancreatic cancer
timeFrame: 2.5 years
measure: Duration of Response
timeFrame: 2.5 years
measure: Duration of Stable Disease
timeFrame: 2.5 years
measure: Time to progression (TTP)
timeFrame: 2.5 years
measure: Progression-free survival (PFS)
timeFrame: 2.5 years
measure: Overall survival (OS)
timeFrame: 2.5 years
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Honor Health Research Institute
state: Arizona
city: Tucson
country: United States
facility: University of Arizona Cancer Center
state: Arizona
city: Newport Beach
country: United States
facility: Hoag Memorial Hospital Comprehensive Cancer Center
state: California
city: Denver
country: United States
facility: Sarah Cannon Research Institute
state: Colorado
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
city: Houston
country: United States
facility: MD Anderson Cancer Research Center
state: Texas
city: Seattle
country: United States
facility: Virginia Mason Medical Center
state: Washington
Study officials:
References: